Recently, an improvement in the care of BRAF-mutant CRC was achieved by combining MEK and EGFR inhibitors with the mFOLFOX6 chemotherapy regimen, but about 40% of the cases still were non-responsive [16]. The gene discussed is EGFR; the disease is colorectal carcinoma.